Skip to main content

Table 6 A comparison of HTA and MCDA outcomes (economic criteria included) for 50 % threshold, multiple HTA restrictions imposed

From: Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs

 

HTA

Positive

Negative

Unrestricted

Time restrictions

Limits to specific subpopulation

Finanacial restrictions

Clinical reasons

Economic reasons

MCDA

Positive

Cystadane, Volibris, Torisel

Kuvan, Increlex

Nexavar (HCC), Nplate, Tasigna, Glivec (MM), Yondelis

Tasigna, Yondelis

Elaprase, Fabrazyme, Somavert, Torisel

Fabrazyme, Somavert, Torisel

Negative

Vidaza, Glivec (ALL Ph+), Glivec (MDS/MPD), Revatio, Glivec (DFSP), Glivec (GIST)

Zavesca

Tracleer, Ventavis, Sprycel, Atriance, Revlimid (MM/S)

Zavesca, Atriance, Revlimid (MM/S)

None

Nexavar (RCC)